Equities Analysts Offer Predictions for Genelux Q3 Earnings

Genelux Corporation (NASDAQ:GNLX) – Analysts at HC Wainwright dropped their Q3 2026 EPS estimates for shares of Genelux in a report released on Friday, August 14th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.21) for the quarter, down from their prior estimate of ($0.20). The consensus estimate for Genelux’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Genelux’s Q4 2026 earnings at ($0.19) EPS, FY2027 earnings at ($0.77) EPS, FY2028 earnings at $0.61 EPS, FY2029 earnings at $1.63 EPS and FY2030 earnings at $2.52 EPS.

Genelux (NASDAQ:GNLX) last issued its earnings results on Thursday, August 13th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01).

A number of other equities analysts also recently issued reports on GNLX. Wall Street Zen downgraded Genelux from a “sell” rating to a “strong sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Genelux currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Genelux Stock Performance

Shares of NASDAQ GNLX opened at $2.70 on Tuesday. Genelux has a fifty-two week low of $2.29 and a fifty-two week high of $8.53. The firm has a market capitalization of $121.07 million, a PE ratio of -3.14 and a beta of 0.60. The stock’s 50-day simple moving average is $2.89 and its 200-day simple moving average is $2.77.

Hedge Funds Weigh In On Genelux

Several hedge funds and other institutional investors have recently bought and sold shares of GNLX. GSA Capital Partners LLP acquired a new stake in Genelux during the 2nd quarter valued at approximately $35,000. Jefferies Financial Group Inc. acquired a new stake in Genelux during the fourth quarter valued at approximately $48,000. Squarepoint Ops LLC bought a new position in Genelux during the 4th quarter worth approximately $52,000. Raymond James Financial Inc. grew its position in shares of Genelux by 22.6% in the 2nd quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock worth $83,000 after acquiring an additional 5,333 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Genelux in the 2nd quarter valued at approximately $92,000. 37.33% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Genelux news, Director John W. Smither sold 12,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $2.91, for a total transaction of $34,920.00. Following the completion of the sale, the director owned 91,403 shares of the company’s stock, valued at approximately $265,982.73. The trade was a 11.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John Thomas sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $2.98, for a total value of $29,800.00. Following the completion of the transaction, the director owned 472,784 shares in the company, valued at approximately $1,408,896.32. This trade represents a 2.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 25,868 shares of company stock worth $76,120. Insiders own 7.50% of the company’s stock.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.